Avastin is non-toxic

Article

Avastin (bevacizumab) does not exert any toxic effects on the retina and its function, according to a study published in the January issue of Retina journal.

Avastin (bevacizumab) does not exert any toxic effects on the retina and its function, according to a study published in the January issue of Retina journal.

A team led by Professor Peter Heidushka of the University Eye Hospital Tuebingen, Tuebingen, Germany, examined the retinal function of wild-type mice that received an intravitreal injection of Avastin.

Electroretinography (ERG) was performed on four different groups of mice: group 1) mice were injected intravitreally with BSS; group 2) mice received injections of a vehicle solution; group 3) mice were injected with Avastin solution; group 4) mice received sham surgery. ERG was performed before treatment and one, four, 12, and 25 days post treatment.

ERG parameters were similar in all four groups; no difference could be seen between eyes injected with Avastin and those receiving the vehicle solution. Bevacizumab immunoreactivity was present in the retina 30 mins after Avastin injection, but this was no longer detectable 25 days later.

The authors therefore concluded that Avastin does not have any harmful effects on the retina or its function; it penetrates the retina quickly and safely after injection.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.